Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.3...
Maxim Group analyst Jason McCarthy downgrades Brainstorm Cell (NASDAQ:BCLI) from Buy to Hold.
BrainStorm Cell Therapeutics Inc. shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced i...
https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm
Key findings include:90% of participants (9/10) survived more than five years from the onset of ALS symptoms, compared to publi...
